ERBB2 and breast cancer: While other data show that use of NAC has increased for all breast cancer subtypes, national trends show the largest increase in the triple-negative and HER2+ subtypes, likely reflecting selection of patients who are most likely to have robust response.20,21 We found this to be true in ILC as well, despite the very small proportion with triple-negative and HER2+ disease.